The Oral Strategy trial [1] studied patients with active rheumatoid arthritis (RA). They had all responded inadequately to methotrexate, the dominant conventional disease modifying drug (DMARD). The key comparison in the trial was the effects of combining different treatments with methotrexate. One treatment was tofacitinib. This is an orally active Janus Kinase (JAK) inhibitor, a relatively new type of drug for RA. The other treatment was adalimumab an established injectable tumour necrosis factor inhibitor biologic therapy for RA. Over 12 months both combined treatments improved disease activity by similar amounts. Their adverse events were comparable.
The non-inferiority head-to-head design used in the Oral Strategy trial is growing in popularity.
It avoids using inactive placebos. Several recent RA trials had this design [2] [3] [4] . Establishing non-inferiority has complexities. Large sample sizes are usually needed. The trial evaluates whether the confidence interval of the difference between treatments falls within the noninferiority margin of the primary outcome. The non-inferiority margin is defined before patients enter the trial. In the Oral Strategy trial the primary outcome -ACR50 responsessignifies clinically important improvements. An appropriately narrow non-inferiority margin was used. The proportion of patients achieving ACR50 responses was numerically greatest with tofacitinib-methotrexate. Secondary outcomes were similar. Its conclusion tofacitinibmethotrexate combinations are non-inferior to adalimumab-methotrexate is robust.
The Oral Strategy Trial and other studies [5, 6] show tofacitinib is effective in RA without major toxicity concerns. It will have a role in some active RA patients. Another oral JAK inhibitors is currently available for active RA. This is baricitinib, which has comparable efficacy and side effect levels [4] . The merits of one of these JAK inhibitor over the other are uncertain. But Assessing risks and benefits in routine clinical practice is difficult. When biologics were introduced there were substantial uncertainties about their risks. Consequently large prospective registers of treated RA patients were established. Together with trials these registers showed biologics increased serious infections. However, the balance of risks and benefits were judged acceptable for patients with severe RA. Oral JAK inhibitors also increase serious infections. This risk is shown in the Oral Strategy trial. Caution is therefore needed when JAK inhibitors are used routinely. Reassuringly, a systematic review of serious adverse events in 117 RA trials found no specific concerns with tofacitinib [7] .
International recommendations vary on the optimal treatment of active RA after inadequate responses to methotrexate. American experts [8] To control active RA some patients are bound to need injectable biologics or oral JAK inhibitors.
Costs were not evaluated in the Oral Strategy trial. Yet they will have crucial roles determining JAK inhibitor use. Biologics for severe, active RA fall within, or above, the upper limits of acceptable cost-effectiveness [12] . JAK inhibitors will only be used to any extent if their costeffectiveness is comparable or better. When treatments have similar efficacy and risks, healthcare funders expect the preferential use of the least expensive option. JAK inhibitors will only be used substantially if their cost is comparable to biosimilars.
The Oral Strategy trial highlighted three benefits from the combination of tofacitinib and methotrexate in active RA. First its efficacy and toxicity are comparable to injectable biologics like adalimumab. Second its onset of action seems equally rapid, Third most patients are able to remain on tofacitinib therapy for 12 months. These findings are extremely encouraging. They show the ongoing benefits of innovation in drug treatment. The trial also underlines the major flaw of all intensive treatment regimens in active RA patients who failed to respond to methotrexate. Only a minority of patients achieve remission with any treatment strategy. While effective RA treatments have expanded greatly in recent years its overall management still has substantial room for improvement.
